Welcome to our dedicated page for Evoke Pharma SEC filings (Ticker: EVOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evoke Pharma, Inc. filings document the company’s completed acquisition by QOL Medical, including material definitive agreement disclosures, tender-offer and merger completion records, common-stock capital structure, and Nasdaq-listed security information before trading ceased. The filing record also includes 8-K disclosures for quarterly financial results and operating updates.
Other Evoke filings record company-specific events tied to GIMOTI, including USPTO patent activity, FDA Orange Book listing plans, and intellectual-property coverage for intranasal metoclopramide in gastroparesis patients. Governance, risk-factor, shareholder, and transaction disclosures appear through material-event reports and related exhibits.
Evoke Pharma, Inc. filed a post-effective amendment on Form S-3 to formally deregister all securities that remained unsold under several existing shelf registration statements. The company explains that this step follows the completion of a merger in which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, with Evoke surviving as a wholly owned subsidiary of QOL Medical, LLC under an Agreement and Plan of Merger dated November 3, 2025. Because of this merger, Evoke has terminated all offerings and sales of its securities under these registrations and is now removing any securities that were registered but never issued.
Evoke Pharma, Inc. has filed a post-effective amendment on Form S-3 to formally remove from registration all securities that remained unsold under several prior shelf registration statements. This step follows the completion of a merger on December 17, 2025, in which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, with Evoke continuing as a wholly owned subsidiary of QOL Medical, LLC.
Because the merger has closed, Evoke has terminated all offerings and sales of its securities under these shelf registrations and is now deregistering any securities that were previously registered but never issued. The filing is an administrative clean-up required by prior undertakings and does not represent a new financing or securities offering.
Evoke Pharma, Inc. filed a post-effective amendment to several Form S-3 registration statements to deregister all securities that were previously registered but remain unsold or otherwise unissued. This action follows the completion of a merger on December 17, 2025, under which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, with Evoke Pharma surviving as a wholly owned subsidiary of QOL Medical, LLC.
Because of this merger, Evoke Pharma has terminated all offerings and sales of its securities under these registration statements and is formally removing any remaining unsold securities from registration, as it had previously undertaken to do. The filing notes that additional details about the merger and the Merger Agreement are available in an Exhibit to a Form 8-K filed on November 4, 2025.
Evoke Pharma, Inc. filed a post-effective amendment on Form S-3 to deregister all securities that remained unsold under several existing shelf registration statements. This step follows the completion of a merger in which QOL-EOS Merger Sub, Inc. was merged with and into Evoke Pharma, leaving Evoke as a wholly owned subsidiary of QOL Medical, LLC.
Because the merger has closed, Evoke has terminated all offerings and sales of its securities under these prior registration statements and is formally removing any securities that were registered but never issued. The filing is an administrative action that implements undertakings previously made in those registration statements.
Evoke Pharma, Inc. is filing a post-effective amendment to its shelf registration statements on Form S-3 to remove from registration all securities that were previously registered but remain unsold. This step follows the completion of a merger on December 17, 2025, in which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma under an Agreement and Plan of Merger dated November 3, 2025.
As a result of this transaction, Evoke Pharma now operates as a wholly owned subsidiary of QOL Medical, LLC, and all offerings and sales of its securities under the affected registration statements have been terminated. The company is fulfilling its prior undertakings by formally deregistering any securities that were registered but not issued when those offerings ended.
Evoke Pharma Inc. director Greg Pyszczymuka filed a report of insider transactions tied to the company’s merger with QOL Medical, LLC. QOL-EOS Merger Sub, Inc. merged into Evoke Pharma effective December 17, 2025, leaving Evoke as a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each outstanding stock option to buy Evoke common stock fully vested, was canceled, and was converted into a right to receive cash. The cash amount for each option is based on the number of underlying shares multiplied by $11.00 minus the option’s exercise price, as specified in the merger agreement.
Evoke Pharma Inc. director Benjamin C. Smeal reported the cash-out of his stock options in connection with the company’s merger with QOL Medical, LLC. A QOL-owned merger subsidiary combined with Evoke Pharma on December 17, 2025, leaving Evoke as a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each option to buy Evoke common stock fully vested, was canceled, and converted into a right to receive cash. The cash amount for each option was based on the number of underlying shares multiplied by $11.00 per share minus the option’s exercise price, paid without interest. The reported transactions include stock options to purchase 5,833 shares at an exercise price of $5.51 and 1,125 shares at an exercise price of $3.453, both of which were disposed of in this process.
Evoke Pharma, Inc. filed a post-effective amendment to its Form S-1 registration statement to deregister all securities that remained unsold under Registration No. 333-275443. This step follows the completion of a merger in which QOL-EOS Merger Sub, Inc. merged with and into Evoke Pharma, with Evoke surviving as a wholly owned subsidiary of QOL Medical, LLC. Because the merger has closed and Evoke has terminated all offerings and sales under this registration statement, the company is formally removing any securities that were registered but not issued.
Evoke Pharma Inc. executive Marilyn R. Carlson reported equity transactions tied to the company’s sale to QOL Medical, LLC. On December 16, 2025, purchasers completed a tender offer to acquire all outstanding Evoke Pharma common shares for $11.00 in cash per share, followed by a merger on December 17, 2025 that made Evoke a wholly owned subsidiary of QOL Medical.
Carlson, the company’s Chief Medical Officer, reported the disposition of 360 shares of common stock and the cancellation of stock options covering 17,291 and 11,000 shares. Under the merger agreement, each outstanding stock option became fully vested and was converted into the right to receive a cash payment equal to the number of underlying shares multiplied by the difference between the $11.00 offer price and the option’s exercise price.
Evoke Pharma director Cam L. Garner reported transactions tied to the company’s sale to QOL Medical. On December 16, 2025, Purchasers completed a tender offer to acquire all Evoke Pharma common shares for $11.00 per share in cash. Garner’s indirectly held 2,330 shares of common stock through Garner Investments, L.L.C., which were disposed of in connection with the deal.
After the tender offer, a merger became effective on December 17, 2025, making Evoke Pharma a wholly owned subsidiary of QOL Medical. At the merger time, each outstanding stock option automatically vested, was canceled, and converted into a cash right equal to the number of option shares multiplied by the difference between the $11.00 offer price and the option’s exercise price. Following these transactions, the reported stock options show a remaining balance of zero.